Title: Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment
in Chinese Healthcare: An EVIDEM Framework Analysis
Version: 3 Date: 13 Mar 2024
Reviewer's report:
This study evaluated two new acid blockers in China, VPZ and TPZ, using the EVIDEM
framework. It involved two expert panels: one assigned weights and scored evidence, while the
other conducted literature reviews and evaluated value. VPZ's value slightly surpassed TPZ's,
with potential for EVIDEM in Chinese healthcare. Overall, the study is novel and worthy
of publication after revisions. My main suggestion is to have statisticians or pharmacologists
carefully review the statistical methods of the study to evaluate their rigor.
Title: Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment
in Chinese Healthcare: An EVIDEM Framework Analysis
Version: 3 Date: 13 Mar 2024
Reviewer's report:
This study evaluated two new acid blockers in China, VPZ and TPZ, using the EVIDEM
framework. It involved two expert panels: one assigned weights and scored evidence, while the
other conducted literature reviews and evaluated value. VPZ's value slightly surpassed TPZ's,
with potential for EVIDEM in Chinese healthcare. Overall, the study is novel and worthy
of publication after revisions. My main suggestion is to have statisticians or pharmacologists
carefully review the statistical methods of the study to evaluate their rigor.
Please review this paper.
user
Title: Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment
in Chinese Healthcare: An EVIDEM Framework Analysis
Version: 3 Date: 13 Mar 2024
Reviewer's report:
This study evaluated two new acid blockers in China, VPZ and TPZ, using the EVIDEM
framework. It involved two expert panels: one assigned weights and scored evidence, while the
other conducted literature reviews and evaluated value. VPZ's value slightly surpassed TPZ's,
with potential for EVIDEM in Chinese healthcare. Overall, the study is novel and worthy
of publication after revisions. My main suggestion is to have statisticians or pharmacologists
carefully review the statistical methods of the study to evaluate their rigor.
assistant